iTeos to Present at the 41st Annual J.P. Morgan Healthcare Conference
iTeos Therapeutics (Nasdaq: ITOS), a biopharmaceutical firm focused on immuno-oncology, announced that CEO Michel Detheux will present at the 41st Annual J.P. Morgan Conference in San Francisco on January 10, 2023, at 8:15 a.m. PST. A live webcast of the event will be accessible on the company's website, with an archived replay available for 30 days post-presentation. iTeos is known for its innovative therapies aimed at enhancing the immune response against cancer, including its lead programs, EOS-448 and inupadenant.
- None.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Tuesday, January 10, 2023 at 8:15 a.m. PST (11:15 a.m. EST).
A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The first antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism, currently progressing in multiple indications in collaboration with GSK. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression into proof-of-concept trials in several indications following encouraging single-agent activity in Phase 1. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
What will iTeos Therapeutics present at the J.P. Morgan Conference 2023?
Where can I watch the iTeos Therapeutics presentation?
What is the focus of iTeos Therapeutics' pipeline?
When is the iTeos Therapeutics presentation scheduled?
What are the main products of iTeos Therapeutics?
